The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

ICP-248 (Mesutoclax) is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the ...

ICP-248 is an orally bioavailable B-cell lymphoma-2 (BCL2) selective inhibitor that promotes the normal process of apoptosis in cancer cells. InnoCare Pharma CEO, chairwoman and co-founder Dr ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

BAD is a pro-apoptotic member of the Bcl-2 family that is tightly regulated by survival factors. Several major signalling pathways influence cell death through their direct effects on the ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...